High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

Table 7 Strength-duration time constant. Secondary endpoint

	W0	W24	W48	Absolute change between W0 and W48	p-value
CIDP	0.21 (0.13;0.36)	0.17 (0.13;0.36)	0.32 (0.12;0.32)	-0.01 (-0.01;0.00)
anti-MAG	0.12 (0.11;0.13)	0.27 (0.12; 0.40)	0.26 (0.18;0.33)	0.08 (0.02;0.14)
CMT1	0.12 (0.12;0.14)	0.31 (0.17; 0.32)	0.39 (0.18;0.40)	0.06 (0.05;0.26)
All patients	0.13 (0.12;0.36)	0.27 (0.12; 0.40)	0.32 (0.14;0.36)	0.05 (-0.01;0.14)	.039

Missing data at W48 were imputed with the LOCF method (W24 for patient #04, CIDP group). The results are expressed in ms as median (IQR), in CIDP group (n = 5), anti-MAG group (n = 5), CMT1 group (n = 5) and in all patients (n = 15). The P-value was calculated with the Wilcoxon signed rank test in all patients (n = 15)

ISSN: 1471-2377